Respiratory Inhalers – our new study reveals trends, R&D progress, and predicted revenues Where is the Respiratory Inhalers market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead Our 181-page report provides 118 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Respiratory Inhalers market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, 8 Products and 3 indications are also forecasted.
Respiratory Inhalers Market Forecasts to 2027, by Application: • Asthma • COPD • Other Respiratory Diseases
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 12 leading national markets: • The US • The EU5 markets – Germany – France – UK – Italy – Spain • Japan • China • India • Russia • Brazil • Mexico
The report also includes profiles and forecasts for some of the leading companies in the Respiratory Inhalers device market, with a focus on the Respiratory Inhalers device segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.
Leading companies and the potential for market growth Overall world revenue for Respiratory Inhalers will surpass $33.2bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing use of Respiratory Inhalers across many types of surgery and increasing ageing population will increase sales to 2027.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Respiratory Inhalers Market report helps you In summary, our 181-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world Respiratory Inhalers market and 2 different segmentations, with 8 product types and 3 applications – discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 12 of the leading national markets – US, Mexico, Brazil, Germany, UK, France, Italy, Spain, Japan, China, India, the Rest of World markets. • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Respiratory Inhalers device market and leading companies. You find data, trends and predictions.
Get our report today The Global Respiratory Inhalers Market 2017-2027: Revenue Prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), by Indication (Asthma and COPD) and Geography. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Respiratory Inhalers Market Overview 1.2 Global Respiratory Inhalers Market Segmentation 1.3 Overview of Findings 1.4 Structure of the Report 1.5 Why You Should Read This Report 1.6 How This Report Delivers 1.7 Key Questions Answered by This Analytical Report 1.8 Who is This Report For? 1.9 Methodology 1.9.1 Primary Research 1.9.2 Secondary Research 1.9.3 Market Evaluation & Forecasting Methodology 1.10 Frequently Asked Questions (FAQ) 1.11 Associated Visiongain Reports 1.12 About Visiongain
2. Introduction to Respiratory Disorders and Therapies 2.1 An Introduction to Respiratory Disorders 2.1.1 Classification of Respiratory Disorders 2.1.2 Asthma 2.1.2.1 Trends in Asthma Prevalence 2.1.2.2 Pathophysiology of Asthma 2.1.2.3 Symptoms of Asthma 2.1.2.4 Treatment of Asthma 2.1.2.5 Guidelines for Asthma Treatment 2.1.2.6 Drug Treatments for Asthma 2.1.3 Chronic Obstructive Pulmonary Disease (COPD) 2.1.3.1 Trends in COPD Prevalence 2.1.3.2 Pathophysiology of COPD 2.1.3.3 Symptoms of COPD 2.1.3.4 Treatment of COPD 2.1.3.5 Drug Treatments for COPD 2.1.3.6 Guidelines for COPD Treatment 2.2 Major Drug Classes in the Treatment of Asthma and COPD 2.2.1 Bronchodilators 2.2.1.1 Beta2-Agonists 2.2.1.2 Anticholinergics 2.2.1.3 Anti-Inflammatory Drugs 2.2.1.4 Corticosteroids 2.2.1.5 Leukotriene Receptor Antagonists 2.2.1.6 Monoclonal Antibodies in the Treatment of Respiratory Disease 2.2.1.7 Combination Drugs 2.2.2 Phases of Clinical Trials 2.2.3 Regulation of Medical Devices 2.2.3.1 The US Approval and Regulation System 2.2.3.2 The EU Approval and Regulation System 2.2.3.3 Post-Marketing Surveillance in the EU
3. Respiratory Inhalers: Global Market 2016-2027 3.1 The Global Respiratory Inhalers Market in 2016 3.2 Leading Respiratory Inhaler Products 3.3 Leading Companies in the Respiratory Inhalers Market 3.4 Respiratory Inhalers: Trends and Developments 3.4.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers 3.4.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD? 3.4.3 Telehealth: A Promising Market Trend 3.4.4 Lifecycle Management Strategies to Counter Patent Expiry 3.4.5 Advanced Inhaler Technologies to Counter Generic Erosion
5. Respiratory Inhalers Market, by Indication 5.1 Asthma: Market Overview 5.2 COPD: Market Overview 5.3 Other Respiratory Diseases
6. Leading National Markets 2016-2027 6.1 Regional Breakdown of the Global Respiratory Inhalers Market 6.2 World Respiratory Inhalers Market Forecast 2016-2027 6.2.1 How will Regional Market Shares Change to 2027? 6.3 The US Respiratory Inhalers Market 2016-2027 6.3.1 The US Respiratory Inhalers Market Forecast 2016-2027 6.3.2 US Respiratory Inhalers Market: Trends and Developments 6.4 EU5 Respiratory Inhalers Market 2016-2027 6.4.1 German Respiratory Inhalers Market Forecast 2016-2027 6.4.2 French Respiratory Inhalers Market Forecast 2016-2027 6.4.3 UK Respiratory Inhalers Market Forecast 2017-2027 6.4.4 Italian Respiratory Inhalers Market Forecast 2017-2027 6.4.5 Spanish Respiratory Inhalers Market Forecast 2017-2027 6.4.6 EU5 Respiratory Inhalers Market: Trends and Developments 6.4.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law 6.4.6.2 France: Social Security Finance Bill 2015 6.4.6.3 UK: Improving Asthma and COPD Patient Outcomes 6.4.6.4 Italy: Austerity Measures Limiting Growth 6.4.6.5 Spain: The Start of Recovery in the Spanish Economy 6.5 Japanese Respiratory Inhalers Market 2016-2027 6.6 BRIC Respiratory Inhalers Market 2016-2027 6.6.1 Chinese Respiratory Inhalers Market Forecast 2016-2027 6.6.2 Indian Respiratory Inhalers Market Forecast 2016-2027 6.6.3 Brazilian Respiratory Inhalers Market Forecast 2016-2027 6.6.4 Russian Respiratory Inhalers Market Forecast 2016-2027 6.7 Mexican Respiratory Inhalers Market Forecast 2016-2027
7. Leading Companies in the Respiratory Inhalers Market 7.1 GlaxoSmithKline (GSK) 7.1.1 GSK: Product Portfolio 7.1.2 GSK: Financial Overview 7.1.3 Recent Developments 7.1.3.1 Japanese Regulatory Approval for Relvar Ellipta 7.1.3.2 FDA Filing of Triple Drug Therapy 7.1.3.3 FDA Approval for Breo Ellipta to Adult Asthma Patients 7.1.3.4 Launch of Combination Drugs 7.1.3.5 GSK Presented Data on Eosinophil Levels and COPD 7.1.3.6 Approval for Arnuity Ellipta 7.1.3.7 Approval for Incruse Ellipta 7.1.3.8 GSK: Products in Development 7.2 AstraZeneca 7.2.1 AstraZeneca: Product Portfolio 7.2.2 AstraZeneca: Financial Overview 7.2.3 Recent Developments 7.2.3.1 FDA Approval for Symbicort in Paediatric Patients 7.2.3.2 Charity-Industry Collaboration 7.2.3.3 FDA approval for Bevespi Aerosphere 7.2.3.4 AstraZeneca Acquired Right to Actavis’ Branded Respiratory Portfolio in US and Canada 7.2.3.5 AstraZeneca Acquired Almirall’s Respiratory Portfolio 7.2.3.6 Takeda Respiratory Portfolio Acquisition 7.2.4 AstraZeneca: Products in Development 7.3 Boehringer Ingelheim 7.3.1 Boehringer Ingelheim: Product Portfolio 7.3.2 Boehringer Ingelheim: Financial Overview 7.3.3 Recent Developments 7.3.3.1 Collaboration with Kaohsiung Medical University 7.3.3.2 Collaboration with Weill Cornell Medicine 7.3.3.3 Collaboration with Qualcomm Incorporated 7.3.3.4 Partnership with Propeller Health 7.3.3.5 FDA Approval for Spiriva Respimat 7.3.3.6 Regulatory Approval for Stiolto Respimat 7.3.3.7 Expansion of Respimat Manufacturing Capacity 7.3.3.8 FDA Approval for Stiverdi Respimat 7.3.4 Boehringer Ingelheim: Respiratory Product Pipeline 7.4 Merck & Co. (Merck) 7.4.1 Merck: Product Portfolio 7.4.2 Merck: Financial Overview 7.4.3 Recent Developments 7.4.4 Merck: Products in Development 7.5 Teva 7.5.1 Teva: Product Portfolio 7.5.2 Teva: Financial Overview 7.5.3 Teva: Recent Developments 7.5.3.1 FDA Approval for RespiClick 7.5.3.2 European Approval for Aerivio Spiromax 7.5.3.3 FDA Approval for ProAir RespiClick (albuterol sulfate) 7.5.3.4 Acquisition of Gecko Health Innovations 7.5.3.5 Partnership with IBM Watson Health 7.5.4 Teva: Products in Development 7.6 Novartis International AG 7.6.1 Novartis: Product Portfolio 7.6.2 Novartis: Financial Overview 7.6.3 Novartis: Recent Developments 7.6.3.1 Partnership with Propeller Health 7.6.3.2 Exclusive License Agreement with Sunovion Pharma 7.6.3.3 Partnership with Qualcomm Incorporated 7.6.3.4 FDA Approval for Utibron Neohaler 7.6.3.5 Novartis Presented Data on Ultibro and Seebri 7.6.3.6 Pfizer Promotes Two Novartis COPD drugs in the UK 7.6.4 Novartis: Products Under Development 7.7 Chiesi Farmaceutici S.p.A. 7.7.1 Chiesi: Product Portfolio 7.7.2 Chiesi: Financial Overview 7.7.3 Chiesi: Recent Developments 7.7.3.1 Regulatory Approval for NEXThaler 7.7.3.2 Chiesi: Products Under Development
8. Qualitative Analysis of Respiratory Inhalers Market 8.1 Market Dynamics 8.1.1 Drivers and Opportunities 8.1.1.1 Growing Burden of Respiratory Diseases 8.1.1.2 Smart Inhalers Provide High Growth Opportunities 8.1.1.3 Triple Drug Therapy for COPD To Offer New Revenue Prospects 8.1.2 Restraints and Challenges 8.1.2.1 Patent Expiry and Generic Competition 8.1.2.2 High Cost Impeding Growth of DPIs In Cost-Sensitive Markets 8.2 Porter’s Five Forces Analysis of the Respiratory Inhalers Market 8.2.1 Rivalry among Competitors [Medium] 8.2.2 Threat of New Entrants [Medium] 8.2.3 Power of Suppliers [Medium] 8.2.4 Power of Buyers [High] 8.2.5 Threat of Substitutes [Low]
9. Conclusions 9.1 Respiratory Inhalers: A Maturing Market 9.2 The Global Respiratory Inhalers Market, 2016 - 2027 9.3 Leading Respiratory Inhalers 9.4 Leading Respiratory Inhaler Companies 9.5 Leading Regional and National Markets 9.6 Global Respiratory Inhalers Market Forecast, 2017-2027 9.7 The Future of Respiratory Inhalers Market
10. Glossary Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Figures Figure 1.1 Ageing Population Estimates 2010 - 2050 Figure 1.2: Global Respiratory Inhalers: Market Segmentation Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016 Figure 2.2 Summary of GOLD Guidance for COPD Treatment Figure 3.1 World Respiratory Inhalers Market: Market Shares (%) for Major National Markets Figure 3.2 Top 5 Respiratory Inhalers: Market Shares (%), 2016 Figure 4.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027 Figure 4.2 Metered Dose Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027 Figure 4.4 Single-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.5 Multi-dose DPI Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.6 Jet Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.7 Ultrasonic Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 4.8 Vibrating-mesh Nebulisers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027 Figure 5.2 World Asthma Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.3 World COPD Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 5.4 World Other Respiratory Diseases Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.1 Respiratory Inhalers Market: Revenues ($m) by Region, 2016 Figure 6.2 World Respiratory Inhalers Market: Market Shares (%) by Region, 2016 Figure 6.3 World Respiratory Inhalers Market Forecast: Revenues ($m) by Region, 2016-2027 Figure 6.4 World Respiratory Inhalers Market: Market Shares (%) by Region, 2016 Figure 6.5 World Respiratory Inhalers Market: Market Shares (%) by Region, 2022 Figure 6.6 World Respiratory Inhalers Market: Market Shares (%) by Region, 2027 Figure 6.7 US Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.8 EU5 Respiratory Inhalers Market Forecast: Revenues ($m) by National Market, 2016-2027 Figure 6.9 German Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.10 French Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.11 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%), 2016-2027 Figure 6.12 Italian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.13 Spanish Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.14 Japanese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.15 BRIC Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.16 Chinese Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.17 Indian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.18 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.19 Russian Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 6.20 Mexican Respiratory Inhalers Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.1 GSK: Major Respiratory Inhalers Revenue ($m), 2016 Figure 7.2 GSK: Major Respiratory Inhalers Revenue Share (%), by Product, 2016 Figure 7.3 GSK: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027 Figure 7.4 AstraZeneca: Major Respiratory Inhalers Revenue ($m), 2016 Figure 7.5 AstraZeneca: Major Respiratory Inhalers Revenue Share (%), by Product, 2016 Figure 7.6 AstraZeneca: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027 Figure 7.7 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), 2016 Figure 7.8 Boehringer Ingelheim: Major Respiratory Inhalers Revenue Share (%), by Product, 2016 Figure 7.9 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027 Figure 7.10 Merck: Major Respiratory Inhalers Revenue ($m), 2016 Figure 7.11 Merck: Major Respiratory Inhalers Revenue Share (%), by Product, 2016 Figure 7.12 Merck: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027 Figure 7.13 Teva: Major Respiratory Inhalers Revenue ($m), 2016 Figure 7.14 Teva: Major Respiratory Inhalers Revenue Share (%), by Product, 2016 Figure 7.15 Teva: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027 Figure 7.16 Novartis: Major Respiratory Inhalers Revenue ($m), 2016 Figure 7.17 Novartis: Major Respiratory Inhalers Revenue Share (%), by Product, 2016 Figure 7.18 Novartis: Major Respiratory Inhalers Revenue ($m) and AGR (%), 2016-2027 Figure 7.19 Chiesi: Foster Inhaler Revenue ($m) and AGR (%), 2016-2027 Figure 8.1 Porter’s Five Forces Analysis of the Respiratory Inhalers Market, 2016-2027 Figure 9.1 Respiratory Inhalers Market Forecast: Revenues ($m) by Product Type, 2016-2027
List of Tables Table 1.1 Respiratory Inhalers Market Forecast Segmented by National Markets: Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 2.1 Classification of Respiratory Diseases Table 2.2 Clinical Trial Phases Table 3.1 Top 5 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016 Table 4.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Product Type, 2016-2027 Table 4.2 World Metered Dose Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.3 World Dry Powder Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027 Table 4.4 Types of Marketed Breezhaler Device Table 4.5 Single-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.6 Multi-dose DPI Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.7 World Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Type, 2016-2027 Table 4.8 World Jet Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.9 World Ultrasonic Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.10 World Vibrating-mesh Nebulisers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.1 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), By Disease Indication, 2016-2027 Table 5.2 World Asthma Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.3 World COPD Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.4 World Other Diseases Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.1 World Respiratory Inhalers Market: Revenues ($m) and Market Shares (%) by Region, 2016 Table 6.2 World Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2027 Table 6.3 Market Shares (%) of Leading Regional Respiratory Inhalers Markets, 2016, 2022 and 2027 Table 6.4 US Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.5 EU5 Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 Table 6.6 German Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.7 French Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.8 UK Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.9 Italian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.10 Spanish Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.11 Japanese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.12 BRIC Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.13 Chinese Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.14 Indian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.15 Brazilian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.16 Russian Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.17 Mexican Respiratory Inhalers Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.1 GSK: Overview, 2016 Table 7.2 GSK: Respiratory Inhaler Products Table 7.3 GSK: Major Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%), By Product Type, 2016-2027 Table 7.4 GSK: Respiratory Therapies Pipeline, 2016 Table 7.5 AstraZeneca: Overview, 2016 Table 7.6 AstraZeneca: Respiratory Inhaler Products Table 7.7 AstraZeneca: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027 Table 7.8 AstraZeneca: Respiratory Therapies Pipeline, 2016 Table 7.9 Boehringer Ingelheim: Overview, 2016 Table 7.10 Boehringer Ingelheim: Respiratory Inhaler Products Table 7.11 Boehringer Ingelheim: Major Respiratory Inhalers Revenue ($m), AGR (%) and CAGR (%), by Product Type, 2016-2027 Table 7.12 Merck: Overview, 2016 Table 7.13 Merck: Respiratory Inhaler Products Table 7.14 Merck: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027 Table 7.15 Teva: Overview, 2016 Table 7.16 Teva: Respiratory Inhaler Products Table 7.17 Teva: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027 Table 7.18 Teva: Respiratory Product Pipeline, 2016 Table 7.19 Novartis: Overview, 2016 Table 7.20 Novartis: Respiratory Inhaler Products Table 7.21 Novartis: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027 Table 7.22 Novartis: Respiratory Product Pipeline, 2016 Table 7.23 Chiesi: Overview, 2016 Table 7.24 Chiesi: Respiratory Inhaler Products Table 7.25 Chiesi: Respiratory Inhalers Revenue ($m), AGR (%), CAGR (%) by Product Type, 2016-2027 Table 9.1 Top 10 Respiratory Inhalers: Revenue ($m) and Market Shares (%), 2016
3M Drug Delivery Systems Actavis Adherium Limited Aerogen Agilent Technology Airssential Allied Healthcare Almirall Astrazeneca Boehringer Ingelheim Briggs Healthcare CareFusion Chiesi Cipla Clement Clarke International Cohero Health DeVilbiss Healthcare Fexicare Gecko Health Innovations GF Health Products GlaxoSmithKline Heyer Medical Hikma Innovate Biomed Inspiro Medical Medline Surgical Merck MRK Healthcare Mylan Nexus 6 Nouvag AG Novartis Omron Healthcare Opko Health Orion Pharma PARI Medical Pfizer Philips Respironics Propeller Health Qualcomm Incorporated Roche Schering-Plough Sunovion Pharma Takeda Pharmaceutical Company Limited Teva Pharmaceuticals Vectura Viatris
Organizations/Associations Mentioned in the Report British Lung Foundation Centers for Disease Control and Prevention Centre for Devices and Radiological Health European Databank on Medical Devices European Medicines Agency European Respiratory Society Food and Drug Administration German Ministry of Health Global Initiative for Asthma Global Initiative for Chronic Obstructive Lung Disease IBM Watson Health Kaohsiung Medical University Ministry of Health, Labour and Welfare Mount Sinai Hospital MRC Technology ServicioSanitarioNazionale UK NHS US National Heart, Lung, and Blood Institute US National Institutes of Health Weill Cornell Medicine World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for The Global Respiratory Inhalers Market 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Single-Use Bioprocessing Probes & Sensors market was valued US$2,493.8 million in 2022 and is projected to grow at a CAGR of 15.2% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
